The Top 5 Biosimilar Articles for the Week of August 22

Here are the top 5 biosimilar articles for the week of August 22, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 22, 2022.

Number 5: Vizient’s 2022 Biosimilar Survey found that health care organizations consider interchangeable designations to be very important in prescription decision-making, signaling the interchangeability could play a big role in the adoption of adalimumab biosimilars.

Number 4: Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.

Number 3: The European Commission (EC) authorized Celltrion Healthcare’s bevacizumab biosimilar referencing Avastin for marketing across the European Union, making it the seventh bevacizumab biosimilar to be approved in the region.

Number 2: Craig Burton, from the Association for Accessible Medicines, wrote an opinion piece that argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result. The piece was in response to another opinion piece written by Sarfaraz K. Niazi, PhD, that critiqued arguments expressed by critics of the law, saying that it could help biosimilars.

Number 1: Hadlima, 1 of 7 FDA-approved biosimilars referencing Humira (adalimumab), now will be offered in a high-concentration, citrate-free (100 mg/mL) version, as the FDA had granted the new formulation regulatory approval.

To read all of these articles and more, visit centerforbiosimilars.com.